Clinical Trial Update: Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial is investigating perioperative tislelizumab plus chemotherapy versus chemotherapy alone for MHC-II-positive gastric/GEJ cancer; the study status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Xiangdong Cheng | Conditions: Gastric Cancer Stage | Phase 3 | Status: NOT_YET_RECRUITING